Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2016 - 2026)

Corvus Pharmaceuticals' Other Operating Expenses history spans 6 years, with the latest figure at -$1.2 million for Q1 2026.

  • Quarterly Other Operating Expenses fell 31.5% to -$1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Mar 2026, down 7.11% year-over-year, with the annual reading at -$3.0 million for FY2025, 4.13% up from the prior year.
  • Other Operating Expenses came in at -$1.2 million for Q1 2026, down from -$561000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$551000.0 in Q2 2024 to a low of -$1.2 million in Q1 2026.
  • The 3-year median for Other Operating Expenses is -$780000.0 (2024), against an average of -$813000.0.
  • The largest YoY upside for Other Operating Expenses was 28.08% in 2025 against a maximum downside of 53.9% in 2025.
  • Corvus Pharmaceuticals' Other Operating Expenses stood at -$780000.0 in 2024, then increased by 28.08% to -$561000.0 in 2025, then crashed by 121.75% to -$1.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Other Operating Expenses are -$1.2 million (Q1 2026), -$561000.0 (Q4 2025), and -$617000.0 (Q3 2025).